2025 United States Antibody Protection Revenue Opportunities Report
Description
The 2025 United States Antibody Protection Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest U.S. companies actively involved in antibody protection through research, development, and manufacturing are Johnson & Johnson, Thermo Fisher Scientific, Merck & Co., Inc., and AbbVie. Johnson & Johnson is a leader in monoclonal antibody therapies, notable for products like Darzalex, targeting cancers such as multiple myeloma, with significant revenues from antibody-based drugs. Thermo Fisher Scientific is a top antibody producer, constantly innovating via recombinant antibody technologies and advanced purification methods, maintaining a dominant position in antibody production and related R&D. Merck & Co. invests heavily in monoclonal and polyclonal antibody technology, providing extensive products for diagnostics and therapeutics, supported by a large global network. AbbVie is known for its antibody drug Skyrizi, approved for inflammatory diseases, generating substantial revenue and contributing significantly to antibody treatment advances in the U.S..
These companies benefit from the growing U.S. antibody market, valued at over $559 million in research antibodies alone in 2023, with a projected 4% CAGR, driven by biomedical, oncology, and infectious disease research. The broader antibody therapy market, dominated by monoclonal antibodies (>69% share), is projected to grow significantly, reaching over $669 billion globally by 2033, with North America comprising the largest regional market. These firms lead in antibody drug manufacturing and collaboration, expanding production capacities and engaging in pipeline development and clinical trials for cancer and autoimmune diseases, signaling their critical role in advancing antibody protection technologies in the United States.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest U.S. companies actively involved in antibody protection through research, development, and manufacturing are Johnson & Johnson, Thermo Fisher Scientific, Merck & Co., Inc., and AbbVie. Johnson & Johnson is a leader in monoclonal antibody therapies, notable for products like Darzalex, targeting cancers such as multiple myeloma, with significant revenues from antibody-based drugs. Thermo Fisher Scientific is a top antibody producer, constantly innovating via recombinant antibody technologies and advanced purification methods, maintaining a dominant position in antibody production and related R&D. Merck & Co. invests heavily in monoclonal and polyclonal antibody technology, providing extensive products for diagnostics and therapeutics, supported by a large global network. AbbVie is known for its antibody drug Skyrizi, approved for inflammatory diseases, generating substantial revenue and contributing significantly to antibody treatment advances in the U.S..
These companies benefit from the growing U.S. antibody market, valued at over $559 million in research antibodies alone in 2023, with a projected 4% CAGR, driven by biomedical, oncology, and infectious disease research. The broader antibody therapy market, dominated by monoclonal antibodies (>69% share), is projected to grow significantly, reaching over $669 billion globally by 2033, with North America comprising the largest regional market. These firms lead in antibody drug manufacturing and collaboration, expanding production capacities and engaging in pipeline development and clinical trials for cancer and autoimmune diseases, signaling their critical role in advancing antibody protection technologies in the United States.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
